4Lefebvre PJ,Scheen AJ.The postprandial state risk of cardiovascular disease 〔J〕.DiabetMed,1998,15（Supp1 4）：S63～S68.
5Hatorp V,Huang WC,Strange P.Pharmacokinetic profiles of repaglinide in elderlysubjects with type 2 diabetes 〔J〕.J Clin Endocrinol Metab,1999,84：1475～1478.
6Hatorp V,Oliver S,Su CA.Biavailability of repaglinide,a novel antidiabeticagent,administered orally in tablet or solution form or intravenously in healthy malevolunteers 〔J〕.Int J Clin Pharmacol Ther,1998,36：636～641.
7Chetty DJ,Chien YW.Novel methods of insulin delivery:an update 〔J〕.Crit RevTher Drug Carrier Syst,1998,15：629～670.
8Saudek CD.Novel forms of insulin delivery 〔J〕.Endocrinol Metab Clin NorthAm,1997,26：599～610.
9Kimura T,Sato K,Sugimoto K,et al.Oral administration of insulin as poly （vinylalcohol）-gel spheres in diabetic rats 〔J〕.Biol Pharm Bull,1996,19：897～900.
10Foley JE.Rationale and application of fatty acid oxidation inhibitors in treatmentof diabetes mellitus 〔J〕.Diabetes Care,1992,15：773～784.
